{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:22:54Z","timestamp":1789906974151,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Cancer Australia and the Diagnostics and Technology","award":["501106"],"award-info":[{"award-number":["501106"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["300705"],"award-info":[{"award-number":["300705"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["455521"],"award-info":[{"award-number":["455521"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1006447"],"award-info":[{"award-number":["1006447"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunter Medical Research Institute, the Health Research Council"},{"name":"University of Newcastle and the Calvary Mater Newcastle, Abbott Laboratories, Novartis Pharmaceuticals"}],"content-domain":{"domain":["thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.radonc.2015.06.011","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T19:28:06Z","timestamp":1436297286000},"page":"112-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial"],"prefix":"10.1016","volume":"116","clinical-trial-number":[{"clinical-trial-number":"nct00193856","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Noorazrul","family":"Yahya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Bulsara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim W.","family":"Denham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2015.06.011_b0005","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0010","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose\u2013volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ijrobp.2006.10.042","article-title":"Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer","volume":"67","author":"Cheung","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0020","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2007.04.076","article-title":"Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose\u2013volume analysis of a phase II dose-escalation study","volume":"69","author":"Harsolia","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.radonc.2014.02.006","article-title":"Relationships between bladder dose\u2013volume\/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer","volume":"111","author":"Carillo","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2009.07.1680","article-title":"Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics","volume":"78","author":"Heemsbergen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0035","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.clon.2011.03.001","article-title":"The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 Trial (ISRCTN47772397)","volume":"23","author":"Barnett","year":"2011","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijrobp.2010.09.027","article-title":"Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients","volume":"82","author":"Cozzarini","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0045","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0360-3016(98)00460-X","article-title":"Diabetes mellitus: a predictor for late radiation morbidity","volume":"43","author":"Herold","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0050","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-013-1146-8","article-title":"Nomograms to predict late urinary toxicity after prostate cancer radiotherapy","author":"Mathieu","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2015.06.011_b0055","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.ijrobp.2004.07.715","article-title":"Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68Gy to 78Gy","volume":"61","author":"Peeters","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0060","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.ijrobp.2007.08.076","article-title":"Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity","volume":"70","author":"Karlsdottir","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0065","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.12.034","article-title":"Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies","volume":"48","author":"Wedlake","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2015.06.011_b0070","unstructured":"http: \/\/ clinicaltrials.gov \/show\/NCT00193856."},{"key":"10.1016\/j.radonc.2015.06.011_b0075","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S1470-2045(12)70423-0","article-title":"Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial","volume":"13","author":"Denham","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0080","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2012.09.018","article-title":"Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer","volume":"105","author":"Denham","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.radonc.2008.10.011","article-title":"Assuring high quality treatment delivery in clinical trials \u2013 results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 \u201cRADAR\u201d set-up accuracy study","volume":"90","author":"Haworth","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1754-9485.12025","article-title":"Quality improvements in prostate radiotherapy: Outcomes and impact of comprehensive quality assurance during the TROG 03.04 \u2019RADAR\u2019 trial","volume":"57","author":"Kearvell","year":"2013","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0095","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.radonc.2007.11.013","article-title":"Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system","volume":"86","author":"Ebert","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0100","doi-asserted-by":"crossref","first-page":"N337","DOI":"10.1088\/0031-9155\/55\/11\/N04","article-title":"Comparison of DVH data from multiple radiotherapy treatment planning systems","volume":"55","author":"Ebert","year":"2010","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2015.06.011_b0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.radonc.2012.10.006","article-title":"Bioeffect modeling and equieffective dose concepts in radiation oncology\u2013terminology, quantities and units","volume":"105","author":"Bentzen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0110","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2006.12.064","article-title":"Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer","volume":"68","author":"Skala","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ijrobp.2004.11.013","article-title":"Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation","volume":"62","author":"Dawson","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0120","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0360-3016(95)90159-0","volume":"31","author":"Lent soma scales for all anatomic sites","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2012.05.007","article-title":"Late gastrointestinal and urogenital side-effects after radiotherapy\u2013incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer","volume":"104","author":"Schmid","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2005.10.005","article-title":"Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation","volume":"77","author":"Christie","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology."},{"key":"10.1016\/j.radonc.2015.06.011_b0140","unstructured":"Harrell FE. rms: Regression Modeling Strategies. R package version 4.2-0. 2014."},{"key":"10.1016\/j.radonc.2015.06.011_b0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate \u2013 a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Stat Soc B Met"},{"key":"10.1016\/j.radonc.2015.06.011_b0150","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2005.08.016","article-title":"Prostate position variability and dose\u2013volume histograms in radiotherapy for prostate cancer with full and empty bladder","volume":"64","author":"Pinkawa","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2010.03.014","article-title":"Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45\u2013103 years","volume":"58","author":"Malmsten","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2015.06.011_b0160","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ijrobp.2010.03.040","article-title":"External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS)","volume":"80","author":"Malik","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0165","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.eururo.2013.02.001","article-title":"Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity","volume":"64","author":"Ghadjar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2015.06.011_b0170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2009.03.013","article-title":"Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer","volume":"92","author":"Fonteyne","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0175","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0140-6736(91)90543-X","article-title":"High prevalence of benign prostatic hypertrophy in the community","volume":"338","author":"Garraway","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2015.06.011_b0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0167-8140(02)00060-9","article-title":"The radiotherapeutic injury\u2013a complex \u2019wound\u2019","volume":"63","author":"Denham","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0185","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.radonc.2011.06.010","article-title":"Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer","volume":"101","author":"Alsadius","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0360-3016(02)02726-8","article-title":"Urodynamic changes at 18months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma","volume":"53","author":"Choo","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.06.011_b0195","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.radonc.2007.03.015","article-title":"Bladder extension variability during pelvic external beam radiotherapy with a full or empty bladder","volume":"83","author":"Pinkawa","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0200","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.radonc.2013.09.028","article-title":"Long term rectal function after high-dose prostatecancer radiotherapy: results from a prospective cohort study","volume":"110","author":"Fellin","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.06.011_b0205","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.radonc.2011.01.006","article-title":"Does the planning dose\u2013volume histogram represent treatment doses in image-guided prostate radiation therapy? Assessment with cone-beam computerised tomography scans","volume":"98","author":"Hatton","year":"2011","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015002935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015002935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T18:06:32Z","timestamp":1717956392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814015002935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0167814015002935"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2015.06.011","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2015.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}